Abstract
Purpose: Current opinion suggests that continued abnormal esophageal acid exposure in Barrett's may play a role in progression to dysplasia and cancer. Normalization of esophageal acid has been shown to reduce the expression of proliferating cell nuclear antigen, suggesting that normalization of esophageal acid exposure may be a desirable goal in Barrett's patients. Our goal was to investigate which antisecretory therapy achieves optimal esophageal acid suppression in Barrett's esophagus patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
